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1. Executive	  Summary	  
The	   results	   of	   the	  pilot	   demonstrated	   that	   a	  pharmacist	   delivered	   vaccinations	   services	   is	  
feasible	   in	   community	   pharmacy	   and	   is	   safe	   and	   effective.	   The	   accessibility	   of	   the	  
pharmacist	   across	   the	   influenza	   season	   provided	   the	   opportunity	   for	   more	   people	   to	   be	  
vaccinated,	  particularly	  those	  who	  had	  never	  received	  an	  influenza	  vaccine	  before.	  	  
Patient	   satisfaction	  was	   extremely	   high	  with	   nearly	   all	   patients	   happy	   to	   recommend	   the	  
service	  and	  to	  return	  again	  next	  year.	  Factors	  critical	  to	  the	  success	  of	  the	  service	  were:	  
1. Appropriate	  facilities	  
2. Competent	  pharmacists	  
3. Practice	  and	  decision	  support	  tools	  
4. In-­‐store	  implementation	  support	  
We	  demonstrated	   in	   the	  pilot	   that	   vaccination	   recipients	   preferred	   a	  private	   consultation	  
area.	  	  As	  the	  level	  of	  privacy	  afforded	  to	  the	  patients	  increased	  (private	  room	  vs.	  booth),	  so	  
did	  the	  numbers	  of	  patients	  vaccinated.	  We	  would	  therefore	  recommend	  that	  the	  minimum	  
standard	   of	   a	   private	   consultation	   room	   or	   closed-­‐in	   booth,	   with	   adequate	   space	   for	  
multiple	   chairs	   and	   a	   work	   /	   consultation	   table	   be	   considered	   for	   provision	   of	   any	  
vaccination	   services.	   The	   booth	   or	   consultation	   room	   should	   be	   used	   exclusively	   for	  
delivering	  patient	   services	  and	  should	  not	   contain	  other	  general	  office	  equipment,	  nor	  be	  
used	  as	  storage	  for	  stock.	  
The	   pilot	   also	   demonstrated	   that	   a	   pharmacist-­‐specific	   training	   program	   produced	  
competent	   and	   confident	   vaccinators	   and	   that	   this	   program	   can	   be	   used	   to	   retrofit	   the	  
profession	   with	   these	   skills.	   As	   vaccination	   is	   within	   the	   scope	   of	   pharmacist	   practice	   as	  
defined	  by	  the	  Pharmacy	  Board	  of	  Australia,	   there	   is	  potential	   for	   the	  universities	   to	   train	  
their	  undergraduates	  with	  this	  skill	  and	  provide	  a	  pharmacist	  vaccination	  workforce	   in	  the	  
near	   future.	   It	   is	   therefore	   essential	   to	   explore	   appropriate	   changes	   to	   the	   legislation	   to	  
facilitate	  pharmacists’	  practice	  in	  this	  area.	  
Given	  the	   level	  of	  pharmacology	  and	  medicines	  knowledge	  of	  pharmacists,	  combined	  with	  
their	   new	   competency	   of	   providing	   vaccinations	   through	   administering	   injections,	   it	   is	  
reasonable	   to	   explore	   additional	   vaccines	   that	   pharmacists	   could	   administer	   in	   the	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community	   setting.	   At	   the	   time	   of	   writing,	   QPIP	   has	   already	   expanded	   into	   Phase	   2,	   to	  
explore	   pharmacists	   vaccinating	   for	   whooping	   cough	   and	   measles.	   Looking	   at	   the	  
international	   experience	   of	   pharmacist	   delivered	   vaccination,	   we	   would	   recommend	  
considering	  expansion	  to	  other	  vaccinations	  in	  the	  future	  including	  travel	  vaccinations,	  HPV	  
and	  selected	  vaccinations	  to	  those	  under	  the	  age	  of	  18	  years.	  
Overall	   the	   results	   of	   the	  QPIP	   implementation	   have	   demonstrated	   that	   an	   appropriately	  
trained	  pharmacist	  can	  deliver	  safely	  and	  effectively	  influenza	  vaccinations	  to	  adult	  patients	  
in	  the	  community.	  The	  QPIP	  showed	  the	  value	  that	  the	  accessibility	  of	  pharmacists	  brings	  to	  
public	  health	  outcomes	  through	  improved	  access	  to	  vaccinations	  and	  the	  ability	  to	  increase	  
immunisation	  rates	  in	  the	  general	  population.	  Over	  time	  with	  the	  expansion	  of	  pharmacist	  
vaccination	  services	  this	  will	  help	  to	  achieve	  more	  effective	  herd	  immunity	  for	  some	  of	  the	  
many	  diseases	  which	  currently	  have	  suboptimal	  immunisation	  rates.	  
2. Background	  
Suboptimal	   uptake	   of	   vaccinations	   is	   an	   ongoing	   global	   issue.	   Pharmacist	   delivered	  
vaccinations	   in	   the	   community	   setting	   have	   become	   part	   of	   the	   solution	   in	   the	   United	  
Kingdom,	  United	  States,	  Canada,	  Portugal	  and	  most	   recently	  New	  Zealand.	  Some	  of	   these	  
countries	   have	   seen	   pharmacists	   administering	   vaccines	   for	   over	   a	   decade.	   The	   type	   of	  
vaccines	   delivered	   varies	   by	   country,	   but	   includes	   influenza,	   travel	   vaccinations,	   HPV,	  
measles	   and	   whooping	   cough.	   Pharmacists	   may	   develop	   their	   competency	   to	   deliver	  
vaccinations	   and	   provide	   immunisation	   services	   through	   either	   their	   undergraduate	  
qualification,	   or	   undertake	   pharmacist	   specific	   training	   programs	   designed	   specifically	   to	  
retrofit	  the	  profession	  in	  each	  country.	  
Within	  the	  Australian	  context	  there	  have	  been	  several	  key	  barriers	  to	  pharmacists	  providing	  
immunisation	  services:	  
1. Lack	  of	  legislative	  framework	  
2. Competency	  gaps	  
3. Attitudes	  of	  other	  health	  professionals	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Community	   pharmacies	   across	   Australia	   have	   started	   providing	   immunisation	   services	  
through	  the	  delivery	  of	  a	  Nurse-­‐Immuniser	  model.	  This	  model	  limits	  pharmacies	  to	  able	  to	  
providing	   one	   day	   or	   variable	   short	   sessions	   across	   an	   entire	   influenza	   season.	   	   This	  
restricted	   access	   to	   the	   service	   in	   the	   community	   and	   provided	   limited	   options	   for	  
spontaneous	  or	  opportunistic	  vaccination.	  	  
Early	   2013	   saw	   the	   release	   of	   the	   Pharmaceutical	   Society	   of	   Australia	   Guidelines	   for	   the	  
provision	  of	  immunisation	  services	  in	  community	  pharmacy,	  covering	  the	  current	  Australian	  
standard	  of	  care,	  being	  the	  Nurse-­‐Immuniser	  model.	  Given	  that	  pharmacist	  immunisation	  is	  
standard	   practice	   in	   other	   western	   countries	   the	   Pharmacy	   Guild	   of	   Australia	   (Qld)	   and	  
Pharmaceutical	   Society	   of	   Australia	   (Qld)	   continued	   to	   raise	   the	   possibility	   with	   the	  
Government	   the	   amendments	   to	   legislation	   could	   be	   made	   that	   would	   allow	   Australian	  
pharmacists,	  initially	  in	  Queensland	  in	  this	  case,	  to	  offer	  this	  service.	  	  Similar	  conversations	  
were	  had	  in	  jurisdictions	  around	  Australia	  by	  the	  professional	  organisations.	  
Leading	   into	   2013,	   there	   were	   record	   numbers	   of	   influenza	   cases	   and	   several	   measles	  
outbreaks	  across	  the	  country.	  The	  Grattan	  Institute	  report	  on	  Australia’s	  health	  workforce,	  
released	   in	   September	   2013,	   identified	   the	   possibility	   of	   expanding	   the	   scope	   for	  
pharmacists’	  practice	  to	  include	  vaccination	  to	  assist	  in	  alleviating	  the	  shortfall	  in	  services	  in	  
rural	  areas.	  This	  was	  seen	  as	  a	  potentially	  valuable	  addition	  to	  the	  preventative	  healthcare	  
mix.	  
Late	  September	  2013	  saw	  a	  communication	  from	  the	  Chief	  Health	  Officer	  of	  the	  Queensland	  
Department	  of	  Health,	  Dr	  Jeanette	  Young,	  received	  by	  the	  Presidents	  of	  the	  Qld	  Branches	  of	  
Pharmaceutical	   Society	   of	   Australia	   and	   Pharmacy	   Guild	   of	   Australia.	   She	   invited	   the	  
organisations	   to	   consider	   the	   possibility	   of	   a	   trial	   of	   pharmacist-­‐administered	   influenza	  
vaccinations	   in	   community	   pharmacy.	   This	   trial	   was	   to	   be	   targeted	   at	   consumers	   not	  
covered	   under	   the	   National	   Immunisation	   Program	   (NIP),	   with	   appropriate	   evaluation	   on	  
safety,	   feasibility,	   training,	   infrastructure	   and	   governance.	   This	   was	   the	   genesis	   of	   Qld	  





The	   Governance	   of	   the	   pilot	   was	   discussed	   at	   the	   outset	   between	   the	   Presidents	   of	   the	  
Pharmaceutical	   Society	  of	  Australia	   (Qld)	   and	  Pharmacy	  Guild	  of	  Australia	   (Qld)	  Branches,	  
and	   representatives	   from	  the	  Department	  of	  Health.	   It	  was	  considered	  crucial	   that	  all	   key	  
stakeholders	  were	  involved	  to	  provide	  input	  into	  both	  the	  design	  and	  implementation	  of	  the	  
pilot.	   It	   was	   also	   considered	   important	   for	   the	   credibility	   of	   the	   data	   produced,	   that	   the	  
academic	   community	   should	   take	   the	   lead	   in	   the	   research	   design	   of	   the	   pilot.	   The	  
professional	  organisations	  provided	  a	  small	  amount	  of	  funding	  and	  other	  resources	  needed	  
to	  assist	  the	  universities	  with	  the	  implementation	  of	  the	  pilot	  and	  analysis	  of	  the	  data.	  	  
A	   steering	   committee	  of	   key	   stakeholders	   (membership	  noted	   in	   acknowledgements)	  was	  
formed	  and	  invitations	  were	  sent,	  with	  the	  first	  meeting	  held	  in	  November	  2013.	  Prof	  Lisa	  
Nissen	  was	  nominated	  as	  Chair	  of	  the	  Steering	  Committee	  in	  her	  role	  as	  Professor	  and	  Head	  
of	  Clinical	  Sciences,	  Queensland	  University	  of	  Technology	  (QUT),	  supported	  academically	  by	  
Prof	  Beverley	  Glass,	  Chair	  of	  Pharmacy,	  James	  Cook	  University	  (JCU).	  	  
James	   Cook	   University	   was	   chosen	   as	   the	   academic	   partner	   as	   it	   is	   the	   seat	   of	   Rural	  
Pharmacy	  education	  and	  their	  expertise	  would	  be	  valuable	  for	  the	  design	  focus	  on	  rural	  and	  
regional	  access.	  
4. Protocol	  Design	  
Phase	  1	  of	  QPIP	  (QPIP1)	  was	  designed	  to	  evaluate	  in	  an	  Australian	  context,	  the	  international	  
experience	  that	  vaccination	  by	  pharmacists	  in	  a	  community	  pharmacy	  setting	  was	  not	  only	  
feasible,	  but	  also	  safe	  and	  acceptable	  to	  the	  general	  public.	  The	  evaluation	  of	  the	  QPIP	  was	  
approved	  by	  QUT’s	  Human	  Research	  Ethics	  Committee	  (Appendix	  19).	  
The	  protocol	  sought	  to	  address	  the	  following	  questions:	  
1. Are	   pharmacists	   as	   immunisers,	   as	   effective	   as	   the	   current	   standard	   of	   care	   in	  
community	  pharmacy	  (i.e.	  nurse-­‐immunisers)?	  
2. Does	   previous	   delivery	   of	   immunisation	   services	   by	   nurse	   immunisers	   make	   any	  
difference	  to	  the	  implementation	  of	  pharmacist	  vaccination?	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3. Is	   there	   a	   difference	   in	   the	   delivery	   of	   the	   service	   between	  metropolitan	   areas	   and	  
regional	  or	  rural	  settings?	  
4. Are	   there	   any	   barriers	   to	   change	   from	   the	   Nurse-­‐Immuniser	   model	   to	   that	   of	   a	  
Pharmacist-­‐lead	  model	  for	  delivering	  vaccinations	  in	  community	  pharmacy?	  
In	   QPIP1,	   pharmacies	   were	   purposively	   recruited	   to	   target	   specific	   criteria	   to	   ensure	   the	  
data	  needed	  to	  address	  the	  study	  questions	  could	  be	  obtained.	  To	  facilitate	  this,	  the	  QPIP1	  
pilot	  was	  divided	  into	  two	  arms.	  	  
Arm	  one	  allowed	   for	   a	   comparison	  of	   an	  existing	  model	  of	   service	  delivery	   in	   community	  
pharmacy,	  namely	  nurse	  immunisers,	  against	  the	  pilot	  model	  of	  pharmacist	  immunisers.	  For	  
this	  arm,	  the	  research	  team	  worked	  with	  the	  Terry	  White	  Chemist	  group	  (TWC)	  to	  leverage	  
from	   their	   established	   in-­‐pharmacy	   nurse	   immunisation	   program	   to	   collect	   data	   from	  
pharmacist	  immunisers	  in	  their	  pharmacies	  in	  the	  South-­‐East	  Qld	  (SEQ)	  sector.	  In	  2013,	  TWC	  
collected	  patient	  evaluation	  data	  of	  their	  nurse-­‐delivered	  service.	  This	  provided	  the	  baseline	  
information	  about	  the	  in-­‐pharmacy	  service	  and	  the	  acceptability	  of	  nurse-­‐immunisers.	  Arm	  
one	  will	  be	  referred	  to	  as	  the	  ‘SEQ	  arm’	  hereafter.	  
This	  also	  provided	  an	  opportunity	  to	  utilize	  approximately	  50	  TWC	  pharmacies	  in	  SEQ	  who	  
had	  previously	  used	  this	  nurse-­‐delivered	  service	  as	  sites	  in	  QPIP1.	  This	  essentially	  provided	  
pump-­‐primed	   sites	   that	   were	   familiar	   with	   the	   processes	   and	   requirements	   for	   an	  
immunisation	  service.	  The	  difference	  would	  be	  that	  a	  pharmacist	  was	  now	  administering	  the	  
vaccination.	   Thus,	   in	   comparing	   the	   patient	   feedback	   it	   would	   be	   possible	   to	   evaluate	   if	  
pharmacists	  performed	  as	  well	  as	  the	  nurse	  vaccinators.	  
The	  second	  arm	  was	  designed	  to	  evaluate	  barriers	  and	  facilitators	  to	  implementation	  of	  the	  
pilot	  model	  of	  a	  pharmacist	  administered	  immunisation	  service,	  particularly	  in	  regional	  and	  
rural	   and	  areas.	   For	   the	   second	  arm,	  an	  expression	  of	   interest	   (EOI)	  was	   called	   for	   across	  
North	  Qld	  (NQ)	  -­‐	  North	  of	  the	  Tropic	  of	  Capricorn,	   for	  pharmacies	  that	  had	  not	  previously	  
hosted	  an	  in-­‐pharmacy	  immunisation	  service.	  The	  EOIs	  were	  circulated	  through	  the	  branch	  
memberships	  of	  PGA-­‐Qld	  and	  PSA-­‐Qld.	  The	  aim	  was	  to	  recruit	  approximately	  50	  sites	  giving	  
a	  total	  pilot	  number	  of	  approximately	  100	  pharmacies.	  Arm	  two	  will	  be	  referred	  to	  as	  the	  
‘NQ	  arm’	  hereafter.	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The	   SEQ	   and	   NQ	   arms	   both	   evaluated	   safety,	   adverse	   drug	   reactions	   (ADRs),	   patient	  
satisfaction	   and	   improvements	   in	   vaccination	   access	   (Section	   1	   –	   Pilot	   Protocol,	   and	  
Appendix	   1-­‐18).	   Pharmacies	   and	   pharmacist	   from	   both	   arms	   were	   required	   to	   meet	   the	  
inclusion	  criteria	  listed	  below:-­‐	  
Inclusion	  Criteria	  for	  QPIP1:	  Individual	  pharmacists:	  
• Registered	  Pharmacist	  with	  Pharmacy	  Board	  of	  Australia	  (NOT	  INTERN)	  
• Undergone	  appropriate	  immunisation	  training	  	  
o Provided	  by	  PSA-­‐Qld	  for	  the	  QPIP	  trial	  	  
• Current	  First	  Aid	  Certificate,	  and	  cardio	  pulmonary	  resuscitation	  (CPR)	  certification	  
• Appropriate	  professional	  indemnity	  cover	  for	  immunisation	  scope	  of	  practice	  
	  
Inclusion	  Criteria	  for	  QPIP1:	  Pharmacies:	  
• Authorised	  pharmacy	  premise	  (immunisation	  to	  occur	  only	  in	  QPIP	  approved	  site)	  
• QCPP	  (Quality	  Care	  Pharmacy	  Program)	  accredited	  pharmacy	  
• Access	  to	  GuildCare®	  software	  	  
• Appropriate	  indemnity	  cover	  for	  the	  business	  for	  immunisation	  scope	  of	  practice	  
• A	  least	  TWO	  pharmacists	  on	  duty	  when	  immunisation	  is	  being	  provided	  
• Appropriate	  facilities	  to	  host	  immunisation	  (ADR	  management,	  infection	  control,	  privacy)	  
	  
5. Data	  Collection	  
It	  was	  anticipated	   there	  would	  be	  over	  10,000	  vaccinations	  provided	  during	   the	  course	  of	  
the	  pilot.	  Community	  pharmacy	  is	  a	  busy	  environment	  and	  it	  was	  thus	  necessary	  to	  provide	  
data	  collection	  tools	  to	  assist	  the	  pharmacists	  in	  delivering	  their	  service,	  whilst	  not	  imposing	  
a	  constraint	  that	  would	  make	  the	  service	  cumbersome	  and	  unworkable.	  
The	   GuildCare®	   proprietary	   software	   had	   an	   existing	   module	   for	   the	   delivery	   of	   a	   nurse	  
immunisation	   service	   in	   community	   pharmacy.	   This	   software	   also	   had	   the	   capacity	   for	   its	  
data	  to	  be	  interrogated	  from	  the	  back	  end	  and	  be	  de-­‐identified.	  Given	  the	  time	  constraints,	  
 12	  
 
it	  was	  decided	  the	  pilot	  would	  use	  an	  adapted	  version	  of	  the	  existing	  proprietary	  software,	  
which	  would	   contain	   a	  module	   that	   supported	   pharmacist	   delivered	   vaccination	   services.	  
The	  software	  would	  also	  form	  a	  patient	  record	  and	  decision	  support	  tool	  for	  the	  pharmacist.	  
Prof	   Lisa	  Nissen	   (QUT)	   and	  Mr	   Chris	   Campbell	   (TWC)	   assisted	   in	  with	  modification	   to	   the	  
module	   to	   combine	   it	   with	   the	   documentation	   and	   data	   required	   in	   the	   QPIP	   protocol.	  
However,	  not	  all	  data	  collection	  could	  be	  automated	  and	  patient	  satisfaction	  surveys	  and	  7-­‐
day	  follow	  up	  surveys	  were	  required	  to	  be	  completed	  manually.	  
6. Constraints	  
 Legislative	  Framework	  (i)	  
Influenza	   vaccines	   are	   a	   Schedule	   4	   ‘Prescription	   Only’	   medicine	   and	   so	   supply	   would	  
normally	  be	  upon	  presentation	  of	  a	  prescription	  from	  an	  authorized	  person,	  which	  did	  not	  
include	   pharmacists	   at	   the	   time	   of	   the	   pilot.	   In	   addition,	   pharmacists	   are	   not	   able	   to	  
“administer”	  medications	  other	  than	  methadone	  via	  controlled	  means.	  	  
To	  enable	  a	  pharmacist	  to	  provide	  influenza	  vaccinations,	  an	  application	  under	  Section	  18	  of	  
the	  Health	  Drugs	  and	  Poisons	  Regulation	  was	  submitted	  in	  December	  2013	  to	  the	  Office	  of	  
the	   Chief	   Health	   Officer.	   The	   approval	   was	   granted	   for	   pharmacists	   to	   “supply	   and	  
administer	   influenza”	   vaccinations	   according	   to	   the	   QPIP1	   protocol	   (Section	   1	   -­‐	   Plot	  
Protocol,	   and	   Appendix	   1-­‐18).	   This	   allowed	   pharmacists	   who	   completed	   QPIP	   training	   to	  
provide	  and	  administer	  influenza	  vaccinations	  only	  at	  an	  approved	  QPIP	  site	  (Appendix	  20).	  
 Competency	  gaps	  and	  training	  (ii)	  
A	  factor	  critical	  to	  the	  success	  of	  the	  pilot	  was	  ensuring	  pharmacists	  participating	  in	  the	  pilot	  
were	   competent	   in	   providing	   vaccinations.	   The	   Pharmacy	   Board	   of	   Australia	   (PBA)	   had	  
recently	  mapped	   the	   competencies	   for	   pharmacists	  with	   those	   of	   nurse	   immunisers,	   and	  
identified	  there	  was	  significant	  overlap.	  The	  competency	  gaps	  identified	  were	  required	  to	  be	  
addressed	   by	   the	   training	   programs,	   with	   the	   addition	   of	   the	   key	   competency;	  
administration	   of	   injections.	   The	   result	   of	   the	   mapping	   reflected	   the	   existing	   knowledge	  
pharmacists	   possessed	   in	   medication	   management,	   including	   vaccination	   administration,	  
the	  declining	  patient	  and	  cold	  chain	  considerations.	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Given	  the	  need	  for	  a	  tailored	  training	  program	  to	  address	  pharmacist-­‐specific	  competency	  
gaps	   and	   the	   short	   timeline	   for	   implementation	   of	   the	   pilot,	   the	   decision	   was	   made	   to	  
consult	  Canadian	  colleagues	  who	  have	  been	  training	  pharmacists	  for	  the	  administration	  of	  
injections,	   including	   vaccinations	   for	   many	   years.	   The	   Alberta	   Pharmacists	   Association’s	  
“Administering	  Injection	  and	  Immunisation	  Preparation	  Course”	  was	  used	  as	  a	  basis	  for	  the	  
development	  of	  an	  Australianised	  training	  program	  for	  QPIP1	  pharmacists.	  	  
This	  course	  has	  a	  proven	  track	  record	  in	  retrofitting	  the	  profession	  for	  this	  new	  service,	  and	  
providing	   the	   relevant	   and	   specific	   competencies	   required	   by	   currently	   practicing	  
pharmacists.	  This	  training	  course	  was	  to	  provide	  registered	  pharmacists	  in	  Qld	  who	  met	  the	  
pre-­‐requisite	   requirements,	  with	   the	   knowledge,	   skills	   and	   competencies	   to	   establish	   and	  
deliver	  a	  successful	  immunisation	  service	  in	  community	  pharmacy,	  including	  administration	  
of	   injections.	   The	   Pharmaceutical	   Society	   of	   Australia	   (Qld)	   Branch	   facilitated	   the	   design,	  
development	  and	  implementation	  of	  the	  pharmacist	  training	  for	  QPIP1.	  
 Attitudes	  of	  other	  Health	  Professionals	  (iii)	  
There	  was	  opposition	  to	  the	  concept	  of	  pharmacists	  vaccinating	  expressed	  in	  the	  media	  by	  
various	   medical	   organizations,	   though	   this	   was	   not	   unexpected	   given	   our	   previous	  
experiences	   with	   health	   practitioner	   scope	   of	   practice	   expansion.	   However,	   within	   the	  
context	  of	  QPIP1,	  there	  was	  a	  significant	  impact	  on	  the	  implementation	  from	  the	  aggressive	  
and	  relentless	  campaign	  run	  by	  the	  “Revive”	  nurse	  clinic	  group	  from	  Western	  Australia	  who	  
sought	   to	   have	   the	   QPIP	   stopped.	   Revive	   are	   a	   private	   company	   who	   supplied	   nurse	  
immunisation	   services	   to	   pharmacies	   and	   other	   workplaces.	   The	   steering	   committee	   and	  
research	   team	  were	   surprised	   that	  opposition	  had	   come	   from	   this	  part	  of	   the	   sector,	   but	  
understood	   that	   the	   existing	   business	   model	   provided	   for	   pharmacy	   of	   nurse-­‐delivered	  
services	  was	  now	  being	  challenged.	  
 Timing	  (iv)	  
A	  start	  date	  of	  1	  April	  2014	  was	  selected	  to	  ensure	  the	  general	  public	  had	  adequate	  access	  
to	   influenza	   vaccinations	   in	   time	   for	   the	   2014	   influenza	   season.	   We	   acknowledge	   that	  
starting	  earlier	  may	  have	  allowed	  pharmacists	  to	  catch	  the	  first	  part	  of	  the	  season.	  However,	  
the	  April	   1st	   date	   still	   only	   provided	   a	   lead	   time	  of	   six	  months	   to	   design	   the	   pilot,	   obtain	  
regulatory	  approvals,	  obtain	  ethics	  approval,	   recruit	  pharmacies,	  design,	  write	  and	  deliver	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training	  for	  over	  150	  pharmacists,	  and	  design	  practice	  support	  tools	   for	  use	   in	  community	  
pharmacy.	   The	   successful	   launch	   on	   April	   1st	   was	   the	   result	   of	   all	   organisations	   and	  
stakeholders	  striving	  to	  achieve	  a	  common	  goal	  and	  the	  hard	  work	  of	  all	  those	  involved	  in	  
the	  implementation	  stage.	  
7. Vaccination	  Training	  and	  Credential	  for	  Pharmacists	  
Vaccination	   training	   and	   credentialing	   for	   pharmacists	  was	   provided	   by	   PSA-­‐Qld.	   Through	  
consultation	   with	   the	   steering	   group,	   it	   was	   decided	   that	   pharmacists	   should	   receive	   a	  
“credential”	   to	  participate	   in	  QPIP1,	   and	  be	  authorized	   to	   vaccinate	  under	   the	   Section	  18	  
approval.	   The	   training	   was	   one	   part	   of	   this	   credential,	   as	   a	   current	   First	   Aid	   certificate,	  
Australasian	   Society	   of	   Clinical	   Immunology	   and	   Allergy	   (ASCIA)	   training	   and	   being	   a	  
registered	   pharmacist	   provided	   the	   pre-­‐requisite	   background	   to	   which	   the	   newly	   trained	  
competencies	  could	  be	  added.	  	  
An	   outline	   of	   the	   credential	   developed,	   the	   training	   and	   evaluation	   that	   PSA-­‐Qld	   Branch	  
delivered	  to	  QPIP1	  participants,	  and	  pharmacist	  satisfaction	  and	  evaluation	  of	  the	  training	  is	  
described	  below:-­‐	  
 Components	  of	  the	  QPIP1	  Credential	  (i)	  
To	  obtain	  the	  FINAL	  credential,	  participants	  were	  required	  to:-­‐	  
• Be	  a	  registered	  pharmacist	  with	  the	  Pharmacy	  Board	  of	  Australia	  	  
• Hold	  a	  current	  certificate	  in	  HLTAID003	  Provide	  First	  Aid	  or	  HLTFA311A	  Apply	  First	  Aid	  	  
• Hold	   a	   current	   certificate	   in	   HLTAID001	   Provide	   Cardiopulmonary	   Resuscitation	   or	  
HLTCPR211A	  Perform	  CPR	  	  
• Hold	  a	  current	  certificate	  in	  the	  ASCIA	  anaphylaxis	  e-­‐training	  for	  pharmacists	  or	  health	  
professionals	  	  (ASCIA)	  
• Successfully	   complete	   the	   pre-­‐reading	  module	   1	   and	  module	   2	   and	   achieve	   a	   pass	  
mark	  of	  80%	  on	  the	  multiple-­‐choice	  questions	  (PSA-­‐Qld)	  
• Successfully	  complete	  the	  face-­‐to-­‐face	  workshop	  assessment	  (PSA-­‐Qld)	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A	  Certificate	   of	   Credential	  was	  only	   issued	  once	   all	   the	   components	  were	   completed	   and	  
PSA	   staff	   or	   the	   QPIP	   Research	   Assistant	   sighted	   the	   First	   Aid,	   CPR	   and	   ASCIA	   training	  
certificates.	   As	   the	   duration	   of	   the	   pilot	   was	   to	   be	   for	   the	   2014	   influenza	   season,	   the	  
credential	  for	  each	  pharmacist	  was	  given	  an	  initial	  expiry	  date	  of	  31	  October	  2014.	  This	  had	  
the	  possibility	  to	  be	  renewed	  in	  the	  event	  of	  legislative	  change	  or	  extension	  of	  the	  pilot	  and	  
on	   confirmation	   of	   the	   required	   training	   standards	   for	   pharmacists	   by	   the	   Australian	  
Pharmacy	  Council.	  
 The	  Training	  Course	  (ii)	  
The	  training	  part	  of	  the	  credential	  was	  delivered	  in	  two	  sections.	  The	  first	  section	  provided	  
a	   knowledge	   update	   on	   diseases	   and	   vaccines,	   and	   covered	   practical	   considerations	   of	  
implementing	  the	  service	  in	  a	  community	  pharmacy.	  This	  was	  delivered	  through	  an	  online	  
module.	  The	  second	  section	  provided	  the	  new	  practical	  skills	  required,	  and	  reviewed	  the	  
management	   of	   the	   declining	   patient	   through	   active	   role-­‐plays	   simulating	   a	   community	  
pharmacy	  setting.	  
a)	  Section	  ONE	  –	  Pre-­‐study	  online	  (13	  Group	  2	  CPD	  Credits)	  	  
The	   Pre-­‐Study	   included	   reading	  material	   (Module	   1	   and	  Module	   2)	   and	   a	  multiple-­‐choice	  
test.	  To	  successfully	  complete	  the	  Pre-­‐Study,	  participants	  had	  to	  achieve	  at	  least	  80%	  on	  the	  
multiple-­‐choice	  test.	  The	  learning	  objectives	  of	  the	  Pre-­‐Study	  were:-­‐	  
Module	  One	  –	  Diseases	  and	  Vaccines	  	  
1. Discuss	  immunisation	  and	  the	  public	  health	  benefits	  	  
2. Discuss	  immunity	  including	  the	  different	  immune	  responses	  	  
3. Identify	  the	  different	  vaccine	  constituents	  	  
4. Describe	  the	  classification	  and	  types	  of	  vaccines,	  including	  their	  spacing,	  dosing	  and	  
timing	  and	  the	  onset	  and	  duration	  of	  immunity	  	  
5. Review	   Australia’s	   immunisation	   strategy	   and	   the	   epidemiology	   of	   vaccine	  
preventable	  disease	  in	  Australia	  	  
6. Discuss	  the	  key	  organisations	  and	  resources	  in	  immunisation	  in	  Australia,	  including	  
The	  Australian	  Immunisation	  Handbook	  	  
7. Discuss	  the	  NIP	  schedule	  and	  its	  impact	  on	  vaccine	  preventable	  disease	  in	  Australia	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8. Discuss	  the	  myths	  and	  realities	  associated	  with	  immunisation	  	  
Module	  Two	  –	  Practical	  Considerations	  	  
1. Discuss	  the	  role	  of	  the	  pharmacist	  in	  immunisation	  	  
2. Explain	   the	   principles	   and	   procedures	   for	   vaccine	   procurement,	   storage,	   and	  
handling,	  including	  cold	  chain	  breaches	  	  
3. Identify	  workplace	  health	  and	  safety	   issues,	   including	  hand	  hygiene,	   the	  handling	  
and	  disposal	  of	  sharps	  and	  the	  prevention	  and	  management	  of	  needle	  stick	  injuries.	  	  
4. Recognise	  the	  importance	  of	  consumer	  consent,	  confidentiality	  and	  privacy	  	  
5. Describe	  a	  system	  for	  an	  immunisation	  service	  in	  a	  community	  pharmacy	  including	  
administering	  vaccines	  and	  documentation	  requirements	  	  
6. Discuss	   the	   different	   methods	   of	   administration	   of	   vaccines	   and	   recommended	  
injection	  sites	  	  
7. Recognise	   the	   importance	   of	   consumer	   aftercare	   including	   the	   provision	   of	  
vaccination	  statements	  and	  reporting	  to	  immunisation	  registers	  	  
8. Explain	   the	   procedures	   for	   medication	   error	   and	   ADR	   reporting	   including,	  
anaphylaxis	  diagnosis	  and	  management	  	  
	  
b)	  Section	  TWO	  –	  Workshop	  (7	  Group	  2	  CPD	  Credits)	  	  
The	  Workshop	  included	  theory,	  discussion,	  demonstration,	  guided	  practice,	  and	  assessment	  
in	   relation	   to	   delivering	   immunisation	   via	   injections.	   Before	   attending	   the	   face-­‐to-­‐face	  
workshop	  participants	  were	  required	  to:-­‐	  
• Hold	  a	  current	  certificate	  in	  the	  ASCIA	  anaphylaxis	  e-­‐training	  for	  pharmacists	  or	  health	  
professionals	  (ASCIA)	  
• Successfully	   complete	   the	   pre-­‐reading	   Module	   1	   and	   Module	   2	   and	   achieve	   a	   pass	  
mark	  of	  80%	  on	  the	  multiple	  choice	  questions	  	  
1. The	   learning	   objectives	   of	   the	   Workshop	   were:-­‐Describe	   the	   structure	   and	  
assessment	  requirements	  of	  QPIP	  	  
2. Describe	  the	   legal	   framework	  that	  the	  pilot	   is	  operating	  within	  and	  your	  role	  as	  a	  
pharmacist	  and	  immunisation	  provider	  during	  the	  pilot	  	  
3. Identify	  the	  importance	  of	  valid	  consumer	  consent,	  privacy	  and	  confidentiality	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4. Identify,	   report	   and	   manage	   medication	   errors	   and	   adverse	   events	   following	  
immunisation	  	  
5. Describe	  the	  process	  of	  identifying	  and	  treating	  emergencies	  such	  as	  anaphylaxis:	  	  
a. Policies	  	  
b. Procedures	  	  
c. Equipment	  	  
6. Demonstrate	  how	   to	  prepare	   the	  necessary	   equipment	   to	   vaccinate	   a	   consumer,	  
including	  the	  application	  of	  infection	  control	  methods	  	  
7. Demonstrate	  how	  to	  withdraw	  medication	  from	  an	  ampoule	  and	  a	  vial	  	  
8. Demonstrate	  the	  skill	  of	  injections:	  	  
a. Discuss	   preparation	   of	   medications	   for	   intradermal,	   subcutaneous	   and	  
intramuscular	  injections	  	  
b. Discuss	  how	  to	  evaluate	  potential	  injection	  sites	  	  
c. Demonstrate	   the	   location	   of	   appropriate	   sites	   for	   subcutaneous,	   and	  
intramuscular	  injections	  	  
d. Describe	  differences	  in	  technique	  in	  giving	  subcutaneous	  and	  intramuscular	  injections	  	  
9. Discuss	  ways	  to	  decrease	  patient	  anxiety/discomfort	  related	  to	  injections	  	  
	  
 Practical	  Evaluation	  (iii)	  
To	   successfully	   complete	   the	   Workshop	   and	   receive	   a	   Certificate	   of	   Completion	   and	  
Continuing	   Professional	   Development	   (CPD)	   credits,	   a	   workshop	   participant	   under	  
supervision	  of	  a	  credentialed	  nurse	  immuniser	  was	  required	  to:-­‐	  	  
1. Correctly	  demonstrate	  preparation	  of	  a	  medication	  from	  a	  vial	  and	  an	  ampoule	  
2. Work	  in	  pairs	  and	  correctly	  administer	  one	  subcutaneous	  injection	  (locate	  site	  and	  
inject	  into	  each	  other)	  and	  record	  the	  administration	  
3. Work	  in	  pairs	  and	  correctly	  administer	  one	  intramuscular	  injection	  into	  the	  deltoid	  
muscle	  (locate	  site	  and	  inject	  into	  each	  other)	  and	  record	  the	  administration.	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 Training	  satisfaction	  and	  evaluation	  (iv)	  
A	  total	  of	  157	  pharmacists	  completed	  the	  QPIP1	  credential	  through	  14	  face-­‐to-­‐face	  training	  
sessions	   across	   Qld.	   Following	   the	   training,	   participants	   were	   asked	   to	   complete	   a	  
questionnaire	   that	   considered	   aspects	   of	   the	  pre-­‐workshop	  preparation	   (online	  modules),	  
and	   the	   face-­‐to-­‐face	  workshop	  component	  of	   the	   training.	   In	  particular,	  participants	  were	  
asked	  how	  the	  training	  mapped	  to	  the	   learning	  objectives	  provided	  and	  how	   it	  developed	  
their	  confidence	  to	  inject	  /	  immunise	  patients	  following	  the	  course.	  	  
A	  total	  of	  154	  evaluations	  were	  received.	  A	  5-­‐point	  Likert	  scale	  was	  used	  in	  the	  evaluation	  
questionnaire.	   The	   Likert-­‐scale	   for	   questions	   1-­‐5	   had	   the	   anchors	   ‘not	   at	   all’	   to	   ‘entirely’,	  
and	   questions	   6	   -­‐11	   used	   the	   anchors	   ‘poor’	   to	   ‘excellent’.	   Overall	   the	   participants	  were	  
satisfied	  with	  the	  training,	  and	  commented	  that	  the	  pre-­‐reading	  and	  face-­‐to-­‐face	  modules	  
met	  their	  expectations	  and	  was	  relevant	  to	  their	  practice	   (Figure 1).	  When	  asked	  “Now	  that	  
you	  have	  completed	  all	  elements	  of	  the	  QPIP	  credential,	  what	  is	  your	  level	  of	  confidence	  to	  
administer	  injections	  to	  patients?”	  participants	  responded	  positively,	  rating	  their	  confidence	  
as	  ‘very	  good’	  to	  ‘excellent’.	  	  
	  
	  
Figure	  1.Likert	   scale	   scores	   from	   training	  evaluation	  questions	   (n=154/157).	   The	  anchors	  were	  1	  =	  
not	  at	  all,	  to	  5	  =	  entirely	  (Q1-­‐5);	  and	  1	  =	  poor,	  to	  5	  =	  excellent	  (Q6-­‐11).	  






















Q1	   To	  What	  extent	  were	  the	  learning	  objectives	  for	  the	  pre-­‐reading	  modules	  met?	  
Q2	   To	  what	  degree	  were	  the	  pre-­‐reading	  modules	  relevant	  to	  your	  practice?	  
Q3	   Rate	  your	  overall	  satisfaction	  with	  the	  content	  of	  the	  pre-­‐reading	  modules?	  
Q4	   To	  what	  extent	  were	  the	  learning	  objectives	  for	  the	  practical	  training	  met?	  
Q5	   To	  what	  degree	  was	  the	  practical	  training	  relevant	  to	  your	  practice?	  
Q6	   Rate	  your	  satisfaction	  with	  the	  anaphylaxis	  and	  adverse	  event	  section	  of	  the	  practical	  training?	  
Q7	   Rate	  your	  satisfaction	  with	  the	  patient	  management	  section	  of	  the	  practical	  training?	  
Q8	   How	  did	  you	  find	  the	  style	  of	  the	  interactive	  parts	  of	  the	  practical	  training?	  
Q9	   What	  was	  your	  level	  of	  comfort	  with	  giving	  and	  receiving	  injections	  during	  the	  practical	  training?	  
Q10	   Now	  that	  you	  have	  completed	  all	  elements	  of	  the	  QPIP	  credential,	  what	  is	  your	  level	  of	  confidence	  to	  administer	  injections	  to	  
patients?	  
Q11	   Considering	  both	  the	  pre-­‐reading	  and	  the	  practical	  training	  as	  a	  whole,	  what	  is	  your	  overall	  satisfaction	  with	  the	  training	  program	  
for	  the	  QPIP	  credential?	  
	  
It	  was	  also	  important	  to	  note	  that	  while	  participants	  were	  initially	  apprehensive	  about	  giving	  
and	   receiving	   injections	   during	   the	   training	   they	   were	   aware	   that	   this	   was	   a	   critical	  
component	   of	   the	  workshop.	   They	   commented	   that	   although	   having	   even	  more	   practice	  
under	   controlled	   conditions	   in	   the	   course	   would	   always	   be	   good,	   they	   felt	   their	   level	   of	  
confidence	  was	  still	  high	  even	  without	  more	  practice	  (Figure 1).	  The	  trainers	  also	  noted	  that	  
through	  injecting	  each	  other,	  the	  participants	  visibly	  gained	  self-­‐confidence	  in	  their	  ability	  to	  
perform	  their	  new	  skill	  and	  left	  the	  training	  excited	  and	  eager	  to	  begin.	  
8. Results	  and	  Evaluation	  
 QPIP1	  Sites	  (i)	  
A	  total	  of	  80	  pharmacies	  participated	  in	  QPIP1,	  51	  TWC	  pharmacies	  in	  the	  SEQ	  arm	  and	  29	  in	  
the	  NQ	  arm	  (Appendix	  21).	  All	  sites	  were	  required	  to	  display	  their	  site	  certificate	  (Appendix	  
22).	  The	  recruitment	  of	  NQ	  sites	  was	  limited	  by	  the	  need	  to	  have	  two	  registered	  pharmacists	  
on	  duty	  when	  vaccinating,	  and	   issues	  around	  relationships	  with	   local	  general	  practitioners	  
(GP).	  	  	  
Pharmacy	  locations	  and	  type	  ranged	  from	  shopping	  centre	  and	  medical	  centre	  pharmacies	  
to	  suburban	  strip	  pharmacies.	  The	  mix	  included	  banner	  group	  and	  independently	  operated	  
premises.	  The	  top	  three	  pharmacies	  per	  volume	  of	  vaccinations	  provided	  in	  QPIP1	  was	  TWC	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Clifford	  Gardens	  (n	  =	  705),	  TWC	  Myer	  Centre	  (n	  =	  430),	  and	  TWC	  Brookside	  (n	  =	  383).	  The	  
key	  point	  of	  difference	  to	  note	  is	  that	  Clifford	  Gardens	  is	  a	  regional	  site	  (Toowoomba),	  Myer	  
Centre	  is	  a	  metropolitan	  site	  in	  the	  Brisbane	  CBD,	  and	  Brookside	  is	  in	  a	  suburban	  shopping	  
centre	   in	   the	   outer	   Brisbane	   suburbs.	   This	   highlights	   the	   value	   the	   diversity	   community	  
pharmacy	  locations	  provided	  in	  providing	  access	  for	  consumers	  to	  vaccination	  services.	  
The	  average	  number	  of	  vaccinations	  delivered	  per	  store	  was	  194	  and	  34	  in	  the	  SEQ	  and	  NQ	  
arms	  respectively.	  This	  suggested	  that	  the	  previous	  experience	  with	  immunisation	  services	  
by	  nurse	  immunisers	  in	  the	  SEQ	  arm	  might	  have	  enabled	  them	  to	  implement	  the	  pharmacist	  
immunisation	   service	   faster.	   Anecdotally	   this	   has	   been	   reported	   by	   the	   smaller	   NQ	  
pharmacies.	  However,	  further	  evaluations	  of	  sites	  are	  required	  to	  determine	  more	  specific	  
barriers	  and	  facilitators	  to	   implementation	  of	  the	  pharmacist	   immunisation	  service,	  and	  to	  
determine	  if	  this	  was	  the	  case	  across	  all	  pharmacies.	  
 Who	  was	  vaccinated?	  	  (ii)	  
There	   were	   10,889	   vaccinations	   delivered	   in	   the	   pilot.	   More	   females	   than	   males	   were	  
vaccinated	  with	  63%	  of	  vaccinations	  administered	  to	  females	  and	  37%	  to	  males.	  The	  largest	  
age	  group	  vaccinated	  was	  the	  45	  –	  65	  year	  group	  with	  a	  mean	  age	  of	  49	  years	  (Figure	  2).	  It	  
was	  noteworthy	   that	  10%	  of	  people	  overall	  were	  eligible	   for	   free	  vaccines	  under	   the	  NIP,	  
but	  still	  elected	  to	  have	  their	   influenza	  vaccine	  in	  the	  community	  pharmacy,	  despite	  being	  
offered	  referral	  to	  their	  GPs.	  	  
Approximately	  half	  of	   the	  patients	  had	  been	  vaccinated	   in	   the	  previous	  year.	  Almost	  15%	  
had	   never	   received	   an	   influenza	   vaccination	   before,	   and	   approximately	   one-­‐third	   of	   the	  
patients	  had	  previously	   received	  an	   influenza	   vaccination,	  but	  did	  not	   get	   the	   vaccination	  
every	  year,	  with	  some	  not	  having	  been	  vaccinated	  in	  over	  five	  years	  (Figure	  3).	  There	  were	  
no	   differences	   seen	   in	   any	   of	   the	   socio-­‐demographic	   categories	   between	   regional/rural	  
regions	  and	  metropolitan	  sites	  or	  SEQ	  and	  NQ.	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Figure	  2.	  Age	  demographics	  of	  patients	  that	  received	  vaccinations	  from	  pharmacists	  in	  QPIP1.	  
	  
 
Figure	   3.	   Patient’s	   reported	   experience	   on	   whether	   they	   have	   received	   an	   influenza	   vaccine	  
previously,	  and	  how	  frequently	  they	  were	  vaccinated	  against	  influenza.	  
	  
 When	  did	  the	  vaccinations	  take	  place?	  (iii)	  
In	  the	  pilot	  design,	   the	  SEQ	  arm	  featured	  TWC	  pharmacies	  that	  had	  previously	  provided	  a	  
vaccination	   service	   in	   their	   pharmacy.	   TWC	   were	   experienced	   with	   an	   online	   booking	  
system,	  and	  this	  provided	  an	  opportunity	  to	  capture	  booking	  data.	  From	  the	  TWC	  booking	  
data,	   Tuesdays	   and	   Thursdays	   were	   the	   most	   popular	   day	   for	   appointments,	   followed	  
closely	   by	  Wednesday,	   with	   an	   overall	   preference	   for	   midweek	   bookings	   (Figure	   4).	   The	  
most	   popular	   time	   was	   the	   morning,	   at	   10:00	   am,	   followed	   by	   9:00	   am	   and	   11:00	   am	  
respectively	  (Figure	  5).	  
Yes,	  every	  











Figure	  4.	  Terry	  White	  Chemist	  group	  online	  booking	  data,	  comparing	  the	  number	  of	  bookings	  with	  
the	  day	  of	  the	  week	  the	  appointment	  was	  made	  for.	  
 
 
Figure	  5.	  Terry	  White	  Chemist	  group	  online	  booking	  data,	  comparing	  the	  number	  of	  bookings	  with	  
the	  time	  of	  day	  the	  appointment	  was	  made	  for.	  
 
There	  was	  a	  strong	  uptake	  of	  the	  service	  at	  the	  beginning	  of	  the	  pilot,	  with	  the	  peak	  being	  
reached	   mid-­‐June.	   The	   presence	   of	   a	   booking	   system	   with	   complementary	   advertising	  
increased	   the	  penetration	   rates	  of	  vaccination.	  Nevertheless,	  approximately	  half	  of	  all	   the	  
vaccinations	  delivered	   in	  TWC	  were	  generated	   in	   store	  with	  either	  a	   vaccine	  delivered	  on	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  of	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the	   presence	   of	   an	   online	   booking	   system	   appeared	   to	   increase	   the	   efficiency	   of	   vaccine	  
service	  delivery	  for	  the	  TWC	  group.	  
 
Figure	  6.	  Comparison	  of	  the	  frequency	  in	  the	  way	  people	  presented	  for	  their	  influenza	  vaccination	  at	  
the	   Terry	   White	   Chemist	   group,	   i.e.	   walk-­‐ins	   where	   the	   vaccination	   was	   delivered	   ‘on	   the	   spot’,	  
versus	  online	  bookings	  versus	  in	  store	  bookings.	  
 
 Were	  there	  any	  problems	  with	  the	  vaccinations?	  (iv)	  
A	  selection	  of	  patients	  (target	  10%)	  was	  followed-­‐up	  one	  week	  post-­‐vaccination	  to	  ascertain	  
whether	   there	   were	   any	   adverse	   consequences	   to	   note	   from	   the	   QPIP	   service.	   The	   side	  

























Type	  of	  vaccinaUon	  presentaUons	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Table	   1).	   No	   serious	   adverse	   events	   were	   encountered	   in	   the	   pilot.	   There	   were	   a	   small	  
number	   of	   vasovagal	   responses	   in-­‐store,	   and	   the	   majority	   of	   these	   patients	   had	   already	  
indicated	  to	  the	  pharmacist	   that	  this	  was	  a	   likely	  response	  prior	  to	  the	  vaccination.	   It	  was	  
interesting	  to	  note	  that	  patients	  who	  had	  previously	  had	  an	  influenza	  vaccination	  reported	  a	  
lower	  rate	  of	  adverse	  events	  than	  those	  who	  were	  first	  time	  recipients.	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Table	  1.	  Comparison	  of	  the	  reported	  adverse	  effects	  from	  influenza	  vaccine	  between	  people	  who	  
had	  previously	  received	  an	  influenza	  vaccine,	  versus	  those	  who	  were	  ‘vaccine-­‐naïve’.	  
Adverse	  Event	  
Received	  influenza	  
vaccination	  before	  (%)	  
Not	  received	  influenza	  
vaccination	  before	  (%)	  
	  	   N=307	   N=87	  
Pain	  at	  injection	  site	   20.9	   33.3	  
Redness	  at	  injection	  site	   14.0	   28.7	  
Itchiness	  at	  injection	  site	   9.1	   11.5	  
Skin	  infection	  at	  injection	  site	   0.0	   1.2	  
Shivering	  and/or	  chills	   1.0	   1.2	  
Nausea,	  vomiting,	  diarrhoea	   0.3	   1.2	  
Headache	   4.2	   4.6	  
Fever	   1.3	   3.5	  
Cough,	  running	  nose,	  sore	  throat	   5.5	   8.1	  
Muscle	  and/or	  joint	  pain	   3.3	   5.8	  
Excessive	  fatigue	  (more	  than	  normal)	   1.3	   2.3	  
Chest	  infection	   0.3	   0.0	  
Guillian	  Barre	  Syndrome	   0.0	   0.0	  
Nerve	  AE	  (pins	  and	  needles,	  nerve	  pain,	  etc)	   0.0	   0.0	  
Allergic	  reaction	   0.0	   0.0	  
Severe	  allergy	  requiring	  urgent	  treatment/hospitalisation	   0.0	   0.0	  
 
 What	  did	  they	  think	  of	  pharmacist	  vaccination?	  (v)	  
The	   results	   from	   the	   pilot	   of	   pharmacist	   administered	   vaccinations	   compared	   favourably	  
with	  the	  current	  “standard	  care”	  model	  currently	  in	  pharmacies	  i.e.	  nurse	  immunisers.	  The	  
data	   used	   for	   the	   baseline	   information	   about	   the	   acceptability	   of	   nurse	   immunisers	   in	  
community	  pharmacies	  is	  sourced	  from	  the	  TWC	  patient	  evaluation	  data	  from	  2013.	  In	  this	  
survey,	  2690	  patients	  completed	  the	  questionnaire,	  of	  which	  91%	  indicated	  that	  they	  would	  
be	   comfortable	   with	   a	   pharmacist	   administering	   the	   influenza	   vaccine	   should	   that	   be	   an	  
option	  in	  the	  future.	  
The	  broader	  evaluation	  data	  collected	  during	  QPIP	  confirmed	  that	  patients	  were	  happy	  to	  
receive	   their	   vaccination	   from	   pharmacists,	   with	   95%	   of	   patients	   happy	   to	   return	   in	   the	  
future	  (Figure	  7);	  compared	  to	  the	  78%	  from	  the	  2013	  TWC	  group	  who	  reported	  they	  would	  
be	  happy	  to	  come	  back	  again.	  Patients	  were	  also	  satisfied	  with	  the	  professionalism	  of	   the	  
pharmacist	   who	   delivered	   the	   vaccination	   service	   (Figure	   8),	   and	   97%	   of	   patients	   would	  
recommend	  the	  service	  to	  others	  (Figure	  9).	  	  
 26	  
 
The	   level	  of	  acceptance	   from	  patients	  was	  extremely	  high.	  Overall	   the	  patient	  satisfaction	  
with	  the	  service	  was	  96%	  with	  the	  remaining	  4%	  being	  neutral	  (0.6%),	  not	  satisfied	  (0.05%),	  
or	  did	  not	  answer	  the	  question	  (Figure	  10).	  Patients	  consistently	  commented	  that	  this	  was	  a	  
“great	  service,	  and	  I	  hope	  it	  continues”.	   In	  particular,	  many	  patients	  were	  happy	  that	  they	  
could	  “drop-­‐in”	  and	  access	  this	  service	  on	  an	   impulse.	  This	  saw	  people	  who	  usually	  would	  
not	   get	   vaccinated	   because	   they	   could	   not	   be	   bothered	   with	   appointments,	   receive	   a	  
vaccination,	   as	   was	   demonstrated	   by	   almost	   15%	   never	   having	   been	   vaccinated	   before.	  
Patients	  also	  advised	  that	  they	  would	  like	  to	  see	  the	  service	  be	  advertised	  more	  broadly	  and	  
that	  more	  awareness	  of	  the	  service	  should	  be	  created.	  There	  was	  also	  difference	  in	  any	  of	  
the	  patient	  feedback	  between	  rural/regional,	  and	  metropolitan	  sites. 
 
Figure	  7.	  Patients’	  response	  when	  surveyed	  if	  they	  were	  comfortable	  with	  returning	  to	  a	  pharmacy	  
to	  receive	  their	  influenza	  vaccination	  in	  the	  future.	  
 
 
Figure	   8.	   Patients’	   response	   when	   asked	   to	   rank	   their	   vaccination	   experience	   in	   relation	   to	   the	  
professionalism	  of	  the	  pharmacist	  administering	  their	  vaccination.	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Figure	  9.	  Patients’	  response	  when	  surveyed	  if	  they	  would	  recommend	  the	  pharmacist	  administered	  
vaccination	  service	  to	  others.	  
 
 
Figure	  10.	  Overall	  patient	  satisfaction	  with	  the	  pharmacist	  administered	  vaccination	  experience.	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 Facilities	  (vi)	  
While	   a	   variety	   of	   private	   consultation	   facility	   were	   allowed	   in	   the	   QPIP	   pilot,	   the	   most	  
popular	  was	  the	  consultation	  room.	  All	  facilities	  needed	  to	  be	  private,	  but	  a	  separate	  room	  
with	  a	  door	  was	  not	  mandatory.	  The	  patient’s	  preference	   in	   their	  post	   satisfaction	  survey	  
was	  by	  far	  for	  the	  consultation	  room	  as	  this	  afforded	  the	  highest	  level	  of	  privacy.	  Stores	  that	  
had	  private	  rooms	  performed	  better	  on	  vaccination	  volume	  than	  stores	  that	  had	  a	  private	  
area/booth,	  which	  performed	  better	  than	  stores	  that	  used	  a	  screen	  to	  partition	  off	  a	  private	  
area.	  
Overall	  94%	  of	  patients	  were	  satisfied	  with	  the	  premises	  and	  the	  facilities.	  When	  specifically	  
asked	   about	   the	   premises	   and	   the	   facilities	   provided,	   both	   those	   who	   were	   completely	  
satisfied	  and	  the	  small	  amount	  of	  people	  who	  were	  less	  satisfied,	  noted	  that	  improvements	  
could	  be:	  
1. Increase	  the	  number	  of	  chairs	  and	  ensure	  they	  are	  comfortable	  	  
2. Increase	  the	  privacy	  
3. Increase	  the	  space	  
4. Ensure	  the	  space	  is	  utilized	  for	  consultations	  
5. Make	  sure	  there	  is	  less	  clutter	  and	  make	  the	  area	  more	  relaxing	  
6. Ensure	  it	  is	  not	  visible	  to	  the	  public	  




9. Pilot	  Protocol	  
Overview	  
This	  protocol	  was	  developed	  to	  support	  pharmacists	  administering	  influenza	  vaccination	  to	  
enable	  them	  to	  assess	  patient	  suitability,	  record	  patient	  consent	  and	  relevant	  details	  of	  the	  
vaccinations	  administered	  in	  their	  pharmacy,	  whilst	  ensuring	  that	  they	  adhered	  to	  legislative	  
requirements	  and	  that	  the	  patient	  receives	  a	  quality	  service.	  	  
This	   document	   was	   developed	   with	   reference	   to	   information	   from	   the	   PSA’s	   Practice	  
guidelines	   for	   the	   provision	   of	   immunisation	   services	   within	   pharmacy	  
(https://www.psa.org.au/download/practice-­‐guidelines/immunisation-­‐guidelines.pdf)	   and	  
relevant	  international	  literature	  and	  protocols.	  	  
The	   information	   contained	   in	   the	   following	   section	   was	   provided	   to	   the	   pharmacists	   to	  
guide	  the	  implementation	  of	  the	  pilot	  within	  their	  individual	  pharmacies.	  It	  includes	  details	  
for	   staff	   training,	   storage	   of	   vaccines,	   management	   of	   patient	   presentations	   and	  
emergencies.	  This	  document	  was	  linked	  to	  the	  training	  provided.	  
Glossary	  of	  Terms	  
Term	   Definition	  
Patient	   Consumer	  who	  visits	  store	  and	  requests	  a	  vaccination	  	  
Vaccination/vaccine	   An	  antigenic	  substance	  prepared	  from	  the	  causative	  agent	  of	  a	  disease	  or	  a	  
synthetic	  substitute,	  used	  to	  provide	  immunity	  against	  one	  or	  several	  diseases	  
e.g.	  influenza	  
Pharmacist	   Pharmacist	  qualified	  and	  trained	  in	  providing	  the	  vaccine	  
Immunisation	  service	  area	   Private	  area	  where	  the	  patient	  receives	  a	  vaccination	  
Required	  Resources	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Staff	  roles	  and	  training	  
To	   allow	   for	   appropriate	  workflow	   and	   consistent	   delivery	   of	   this	   service,	   it	   is	   advised	   to	  
inform,	   and	   where	   appropriate,	   train	   staff	   members	   about	   the	   service	   the	   pharmacy	   is	  
providing	  patients	  and	  their	  role	  in	  the	  pharmacy’s	  procedure.	  A	  “Clinical	  Champion”	  within	  
the	  pharmacy	  can	  aid	  in	  the	  workflow	  and	  service	  delivery	  (Appendix	  18).	  
The	  pharmacist	  will:	  
• assess	  the	  patient’s	  suitability	  for	  vaccination	  using	  a	  screening	  checklist	  (Appendix	  4)	  
• obtain	  the	  patient’s	  consent	  to	  be	  vaccinated	  
• ensure	   only	   a	   pharmacist	   who	   has	   undertaken	   QPIP	   training	   administer	   vaccines	   to	  
patients	  	  
• observe	  the	  patient	   for	  15	  minutes	  after	  administering	  the	  vaccine	  to	  ensure	  that	  no	  
adverse	  reaction	  occurs	  
• ensure	  there	  is	  adequate	  provision	  of	  staff	  time	  and	  resources	  to	  promote	  and	  explain	  
the	  vaccination	  service	  to	  customers.	  	  	  
Note:	   Either	   a	   pharmacist	   or	   trained	   staff	  member	   can	   enter	   the	   initial	   patient	   details	   into	   the	  
GuildCare®	  software	  –	  BUT	  only	  the	  pharmacist	  can	  complete	  the	  consenting	  process	  
The	  pharmacist	  will	  be	  a	  registered	  pharmacist	  and	  have	  undertaken	  a	  course	  receiving	  the	  
following	  Australian	  recognised	  qualifications	  or	  equivalent:	  	  
• Perform	  CPR:	  HLTCPR211A	  
• Apply	  First	  Aid:	  HLTFA311A	  (Includes	  CPR)	  
• Emergency	  Management	  of	  Anaphylaxis:	  22099VIC	  
It	  is	  recommended	  that	  additional	  staff	  be	  educated/trained	  in:	  
• their	  role	  in	  emergency	  response	  procedures	  
• the	  pharmacist’s	  role	  in	  administering	  the	  vaccine	  
 31	  
 
• the	  immunisation	  service	  delivery,	  including	  appointment	  arrangements,	  referral	  of	  
customer	  enquiries	  and	  handling	  of	  customer	  complaints	  
• policies	  and	  procedures	  for	  collecting	  patient	  information	  
• privacy	  information	  
• cultural	  safety.	  	  
It	   is	   strongly	   advised	   that	   all	   pharmacy	   staff	   are	  educated	  about	   the	   signs	  of	   anaphylaxis.	  
Refer	  to	  Appendix	  1	  for	  more	  information.	  
Professional	  Indemnity	  Insurance	  
Pharmacists	  (and	  the	  pharmacy)	  must	  have	  professional	  indemnity	  insurance,	  which	  covers	  
immunisation	  as	  within	  the	  scope	  of	  practice,	  and	  ensure	  that	  it	  is	  appropriate	  for	  them	  to	  
administer	  the	  vaccines	  in	  the	  pharmacy.	  	  	  
Facilities	  required	  
Each	   vaccination	   should	   be	   conducted	   in	   a	   screened	   area	   or	   private	   room	   and	   allow	   for	  
confidential	   discussions	   with	   a	   patient	   to	   be	   conducted	   and	   in	   a	   place	   where	   their	  
conversations	  (when	  at	  normal	  speaking	  levels)	  cannot	  be	  overheard	  by	  other	  patients.	  The	  
area	  should	  be	  of	  sufficient	  size	  and	  layout	  to	  accommodate	  an	  efficient	  workflow	  to	  allow	  
for	  the	  patient,	  the	  carer	  (if	  applicable),	  the	  pharmacist,	  as	  well	  as	  consumables,	  equipment	  
and	  documentation	   for	   the	  service.	   It	   is	   important	   to	  ensure	   that	   there	   is	   sufficient	   space	  
and	  appropriate	  surfaces	  for	  the	  pharmacist	  to	  treat	  potential	  adverse	  events.	  Appropriate	  
hand-­‐washing	   facilities	   should	   meet	   Queensland’s	   heath	   requirements	   and	   be	   available	  
within	  the	  pharmacy.	  	  
Adverse	  reactions/emergency	  response	  
There	   should	   be	   an	   area	   for	   the	   patient	   to	  wait	   after	   vaccination,	   so	   the	   pharmacist	   can	  
observe	   the	   patient	   for	   15	   minutes	   to	   ensure	   no	   adverse	   reactions	   occur.	   These	   areas	  
should	  not	  be	  within	   the	  dispensary	  and	  will	   need	   to	  ensure	   there	   is	   adequate	   seating	   (a	  
recommendation	  is	  adjacent	  to	  the	  immunisation	  area).	  
Pharmacists	  should	  use	  discreet	  identifiers	  to	  enable	  a	  quick	  identification	  of	  patients	  who	  
have	   received	   the	  vaccination	  should	   they	   require	   further	  assistance.	  Refer	   to	  Appendix	  1	  
for	  Anaphylaxis	  Management.	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If	  anaphylaxis	  is	  present,	  the	  Initial	  Anaphylaxis	  Response	  Management	  Chart	  (Appendix	  2)	  
or	  equivalent	  should	  be	  followed.	  After	  the	  patient	  has	  been	  taken	  to	  hospital,	  ensure	  that	  
all	   emergency	   equipment	   is	   restocked	   and	   refilled,	   as	   soon	   as	   possible,	   and	   before	  
another	  vaccination	  is	  administered.	  	  
Emergency	  equipment	  should	  be	  checked	  regularly.	  	  
Any	  Adverse	  Reaction	  or	  Effect	  must	  be	  recorded	  using	  GuildCare®	  ADR	  module	  and	  noted	  
in	  the	  Patients	  Vaccination	  Record	  on	  GuildCare®	  (Appendix	  6)	  
Equipment	  required	  
All	  pharmacies	  must	  have	  appropriate	  equipment	  for	  storing	  vaccines	  and	  vaccine	  products,	  
including	   a	   reliable	   and	   stable	   refrigerator	   compliant	  with	  QCPP	   cold	   chain	   requirements.	  
This	  may	  be	  available	   in	   either	   the	   immunisation	  area	  or	   in	   the	  dispensary,	   but	   access	   to	  
vaccines	  and	  vaccine	  products	  is	  restricted	  as	  per	  the	  State	  prescribed	  legislation	  for	  storing	  
controlled	  substances.	  	  
Equipment	   for	   the	  appropriate	  disposal	  of	   sharps	  and	  medical	  waste	  must	  be	  available	   in	  
the	   immunisation	   service	   area,	   as	   described	   in	   the	   current	   edition	   of	   the	   Australian	  
Immunisation	  Handbook.	  Appropriate	  resources	  to	  treat	  consumers	  in	  case	  of	  an	  emergency	  
(including	  a	  displayed	  emergency	  response	  protocol	  and	  emergency	  response	  kit)	  should	  be	  
readily	  available	  in	  the	  immunisation	  service	  area.	  	  
Refer	   to	   Appendix	   3	   for	   a	   full	   list	   of	   required	   equipment,	   which	   is	   the	   Pharmacist	  
Administered	  Vaccination	  Equipment	  Checklist.	  	  
Storage	  and	  handling	  the	  Vaccine	  
To	   ensure	   the	   correct	   process	   for	   receiving	   and	   storing	   vaccines,	   pharmacists	   should	   be	  
familiar	  with	  the	  National	  Vaccine	  Storage	  Guidelines:	  Strive	  for	  5.	  Staff	  will	  also	  need	  to	  be	  
educated	  on	  the	  storing	  of	  vaccines	  and	  monitoring	  of	  the	  refrigerator	  temperature.	  For	  the	  
purposes	  of	  a	  quality	  control	  audit	  for	  the	  QPIP	  project	  the	  following	  QCPP	  documents	  and	  
procedures	  should	  be	  followed	  in	  regard	  to	  vaccine	  refrigerator	  temperature	  records:-­‐	  
• P5A:	  Monitoring	  Refrigerator	  Temperature	  Procedure 
• T5C:	  Refrigerator	  Temperature	  Record	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• T5B	  Equipment	  Calibration/Maintenance	  Schedule	  and	  Record.	  
At	  least	  two	  pharmacists	  should	  be	  responsible	  for	  receipting	  and	  storing	  the	  flu	  vaccine.	  	  
The	  vaccination	  will	  arrive	  in	  a	  secure	  cold	  chain	  storage	  packaging.	  Externally	  the	  packaging	  
will	  have	  a	  date	  and	  time	  label	  that	  advises	  when	  it	  was	  dispatched	  from	  the	  manufacturer.	  
This	  should	  be	  checked	  immediately	  upon	  arrival	  to	  ensure	  that	  the	  arrival	  time	  is	  within	  24	  
hours	  of	  the	  packing	  date	  and	  time.	  	  
The	  delivered	  vaccines	  will	  need	  to	  be	  removed	  from	  the	  cold	  chain	  packaging.	   (Note:	  the	  
vaccines	   should	   never	   be	   stored	  within	   the	   fridge	  without	   removing	   them	   from	   the	   cold	  
chain	  packaging).	  	  
To	   ensure	   that	   the	   hazardous	   waste	   is	   disposed	   of	   correctly,	   QCPP’s	   Infection	   Control	  
procedure	  will	  need	  to	  be	  followed.	  	  
Assessing	  patient	  suitability	  for	  a	  vaccination	  
The	  pharmacist	  should	  complete	  a	  Patient	  Pre-­‐vaccination	  Checklist	  for	  Pharmacist	  form	  to	  
assess	  each	  patient’s	  suitability	  for	  the	  vaccination	  (Appendix	  4).	  Patients	  identified	  as	  being	  
at	   risk	   should	   be	   given	   information	   on	   the	   vaccination	   and	   be	   referred	   to	   their	   primary	  
health	  care	  provider	  for	  further	  discussion	  (a	  referral	  letter	  can	  be	  provided).	  	  
Patients	   travelling	   to	   areas	   of	   considerable	   risk	   or	   those	   who	   have	   chronic	   diseases	   that	  
place	  them	  at	  increased	  risk	  of	  disease	  or	  illness	  during	  their	  trip	  should	  also	  be	  referred	  to	  
their	  primary	  health	  provider.	  	  
Pharmacists	  must	  only	  provide	  advice	  within	  the	  limits	  of	  their	  professional	  knowledge	  and	  
experience	  and	  ensure	  that	  they	  are	  up	  to	  date	  with	  the	   latest	  policy	  advice	  and	  scientific	  
evidence	  around	  the	  immunisation.	  	  
See	  Appendix	  4,	  for	  an	  Example	  Patient	  Pre-­‐vaccination	  Checklist	  for	  Pharmacist	  –	  Influenza.	  
Part	  of	  assessing	  patient’s	  suitability	  for	  the	  vaccine	  will	  require	  the	  patient	  to	  complete	  and	  
sign	   the	   Patient	   Consent	   form,	   printed	   via	   Guildcare®	   (Appendix	   5)	   and	   completion	   of	   a	  
Vaccination	  Recording	  Service	  Report	  –	  using	  GuildCare®	  software	  (Appendix	  6).	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For	  the	  purposes	  of	  the	  QPIP	  patients	  will	  also	  need	  to	  complete	  the	  designated	  consent	  
form	  to	  participate	  in	  the	  research	  study	  by	  signing	  the	  provided	  separate	  documentation.	  
(Appendix	  15)	  
Administering	  the	  vaccination	  (Appendix	  16	  /	  17)	  
1. Take	  the	  patient	  into	  a	  private	  room	  or	  area,	  which	  is	  equipped	  with	  seating,	  and	  a	  
hazardous	  waste	  bin	  to	  discard	  used	  injection	  syringe.	  	  
2. Describe	  the	  injection	  system	  used	  (intradermal,	  subcutaneous	  or	  intramuscular).	  If	  
using	   the	   intradermal	   vaccination,	   describe	   with	   emphasis	   on	   the	   fact	   that	   the	  
different	   injection	   system	   achieves	   the	   same	   efficacy	   as	   alternative	   injection	  
apparatus	   (i.e.	   intradermal	   injection	   only	   needs	   a	   short	   needle,	   but	   achieves	   the	  
same	  vaccination	  efficacy	  as	  longer	  needles,	  different	  brands,	  etc.).	  
3. Discuss	  the	  need	  to	  wait	   in	  the	  pharmacy	  for	  15	  minutes	  after	  vaccination	  (in	  the	  
unlikely	  event	  of	  an	  anaphylactic	  reaction),	  and	  ensure	  that	  the	  customer	  has	  time	  
to	  do	  this.	  	  
4. Explain	   potential	   anaphylactic	   reaction	   symptoms.	   See	   Appendix	   1	   for	   a	   list	   of	  
anaphylactic	   symptoms.	   It	   is	   recommended	   you	  have	   a	   stand-­‐alone	  display	   chart	  
with	  these	  details	  available	  e.g.	  Appendix	  1.	  
5. Check	   that	   the	  patient	   is	  not	  eligible	   for	  a	  government-­‐funded	  vaccination	  or	  has	  
been	   informed,	   if	   they	   are	   eligible.	   Refer	   them	   to	   their	   GP	   or	   carer	   if	   they	   are	  
eligible	  and	  want	  to	  pursue	  the	  funded	  option.	  	  
6. Check	   that	   the	   Patient	   Consent	   Form	   and	   the	  QPIP	   consent	   form	   are	   completed	  
and	  signed	  off.	  	  
7. Check	  that	  the	  vaccine	  is	  the	  correct	  one	  chosen	  for	  use.	  Document	  the	  vaccination	  
name,	   batch	   number	   and	   expiry	   the	   GuildCare®	   Vaccination	   Recording	   Service	  
Report.	  	  
8. Thoroughly	  wash	  and	  dry	  your	  hands	  before	  starting	  the	  procedure.	  Refer	  to	  Hand	  
Hygiene	  Procedure	  (T3M	  -­‐	  QCPP).	  	  
9. Before	  administering	  the	  vaccine	  into	  the	  deltoid	  region	  in	  the	  arm,	  ensure	  that	  the	  
vaccine	   is	   in	  date	  and	  has	  been	  stored	  under	   correct	   storage	  conditions	   (refer	   to	  
National	  Vaccine	  Storage	  Guidelines	  –	  Strive	  for	  5	  (2nd	  edition)	  and	  aforementioned	  
QCPP	  documents.	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10. If	   using	   intradermal	   flu	   vaccination	   follow	   the	   instructions	   provided	   by	   the	  
manufacturer	  (pictorial	  and	  text)	  for	  administering	  intradermal	  vaccination.	  	  
11. If	   using	   an	   intramuscular	   flu	   vaccination	   follow	   the	   instructions	   provided	   by	   the	  
manufacturer	  (pictorial	  and	  text)	  for	  administering	  the	  intramuscular	  vaccination.	  	  
12. Dispose	  of	   the	  used	   injector	   immediately,	  by	  putting	   in	   the	  hazardous	  waste	  bin.	  
Wash	  and	  dry	  hands.	  
13. Advise	  the	  customer	  that	  they	  must	  remain	  in	  the	  pharmacy	  for	  15	  minutes	  in	  case	  
of	   an	   adverse	   reaction	   to	   the	   vaccine.	   Request	   that	   they	   complete	   a	   post-­‐
vaccination	  satisfaction	  questionnaire	  while	  waiting	  (Appendix	  10).	  	  
14. Note	   the	   time	  of	  administration	  and	  end	  of	   the	  15	  minute	  wait	   time.	  During	   this	  
period,	   check	   that	   they	   customer	   is	   feeling	   well	   and	   is	   not	   having	   an	   adverse	  
reaction.	  Keep	  patient	  in	  line	  of	  sight	  at	  all	  times.	  
15. Ensure	  that	  the	  patient’s	  vaccination	  record	  is	  entered	  in	  Guildcare	  and	  complete	  a	  
Patient	   Record	   of	   Immunisation	   (Appendix	   9).	   Including	   documentation	   of	   any	  
ADRs	  (and	  their	  management)	  in	  the	  15min	  observation	  period.	  
16. Ensure	   that	   the	   likely	   post-­‐vaccination	   effects	   and	   how	   to	   deal	   with	   them	   have	  
been	  discussed	  and	   that	   the	  patient	  has	  been	  given	  Frequently	  Asked	  Questions’	  
(Appendix	   7)	   and	   the	   GP	   notification	   letter	   for	   them	   to	   give	   to	   their	   doctor	  
(Appendix	  8),	  if	  requested,	  before	  they	  leave	  the	  pharmacy.	  	  
17. At	  the	  end	  of	  the	  15	  minutes,	  check	  back	  with	  the	  patient,	  and	  if	  they	  are	  feeling	  
well,	  notify	  them	  that	  they	  can	  leave	  the	  pharmacy.	  	  
	  
During	  the	  QPIP	  project	  10%	  of	  patients	  immunised	  will	  receive	  a	  follow-­‐up	  call	  from	  the	  
pharmacist	  to	  collect	  information	  regarding	  their	  responses	  to	  the	  immunisation,	  




Appendix	  1:	  Anaphylaxis	  Management	  -­‐	  Example	  
Signs	  and	  Symptoms	  of	  Anaphylaxis	  
*Ensure	  that	  all	  pharmacy	  staff	  members	  know	  the	  signs	  and	  symptoms	  of	  anaphylaxis.	  See	  table	  below	  for	  
reference.	  *	  
	  
Time	  Scale	   Signs	  and	  symptoms	   Severity	  
Early	  warning	  signs	  (within	  a	  few	  
minutes)	  
Dizziness,	  perineal	  burning,	  
warmth,	  pruritus,	  flushing,	  
urticaria,	  nasal	  congestion,	  
sneezing,	  lacrimation,	  angioedema	  
Mild	  to	  moderate	  
Early	  warning	  signs	  (within	  a	  few	  
minutes)	  
Hoarseness,	  nausea,	  vomiting,	  
substernal	  pressure	  
Moderate	  to	  severe	  
Early	  warning	  signs	  (within	  a	  few	  
minutes)	  
Laryngeal	  oedema,	  dyspnoea,	  
abdominal	  pain	  
Moderate	  to	  severe	  
Late	  and	  life	  threatening	  
symptoms	  




Most	  life	  threatening	  anaphylactic	  events	  begin	  within	  10	  minutes	  of	  vaccination.	  Pharmacy	  shop	  staff	  may	  be	  
the	   first	   people	   to	   notice	   potential	   symptoms	   while	   the	   patient	   is	   waiting	   in	   the	   pharmacy.	   If	   anaphylaxis	  
occurs	  direct	  a	  specific	  person	  to	  call	  an	  ambulance	  while	  other	  staff	  manage	  the	  patient.	  	  
Distinguishing	  anaphylaxis	  from	  a	  faint	  (vasovagal	  reaction)	  
*Ensure	  that	  all	  authorised	  vaccinators	  know	  the	  difference	  in	  symptoms	  between	  anaphylaxis	  and	  fainting.	  	  
See	  table	  below	  for	  reference.	  *	  
	   Faint	  (vasovagal	  reaction)	   Anaphylaxis	  
Onset	   Usually	  at	  the	  time	  or	  soon	  after	  
the	  injection	  
Usually	  a	  delay	  of	  5	  –	  30	  minutes	  
after	  injection	  	  
System	   	   	  
Skin	   Pale,	  sweaty,	  cold	  and	  clammy	   Red,	  raised	  and	  itchy	  rash;	  swollen	  
eyes	  and	  face;	  generalised	  rash	  
	  
Respiratory	   Normal	  to	  deep	  breaths	   Noisy	  breathing	  due	  to	  airways	  
obstruction	  (wheeze	  or	  stridor);	  
respiratory	  arrest	  
Cardiovascular	   Bradycardia;	  transient	  hypotension	   Tachycardia;	  hypotension;	  
dysrhythmias;	  circulatory	  arrest	  
Gastrointestinal	  	   Nausea/vomiting	   Abdominal	  cramps	  
Neurological	  	   Transient	  loss	  of	  consciousness;	  
good	  response	  once	  supine/flat	  
Loss	  of	  consciousness;	  little	  
response	  once	  supine	  flat	  
	  
Be	   prepared	   for	   an	   anaphylactic	   emergency	   and	   ensure	   that	   all	   staff	   members	   know	   the	   initial	  
response/emergency	   procedure	   for	   anaphylaxis.	   Designate	  which	   staff	   roles	  will	   look	   after	   other	   customers	  
and	  who	  will	  call	  the	  ambulance.	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Appendix	  2:	  Initial	  Anaphylaxis	  Response/Management	  -­‐	  Example	  
Initial	  anaphylaxis	  response/management	  chart	  
CALL	  FOR	  HELP	  –	  send	  for	  professional	  assistance	  (ambulance,	  doctor).	  Never	  leave	  the	  individual	  alone.	  	  
ASSESS	  –	  if	  unconscious,	  place	  in	  recovery	  position	  and	  institute	  standard	  procedures	  for	  basic	  life	  support	  
(airway,	  breathing,	  circulation).	  If	  cardiorespiratory	  arrest	  occurs,	  administer	  age-­‐appropriate	  CPR	  and	  life	  
support	  measures.	  	  
ADMINISTER	  ADRENALINE	  –	  dosage:	  1:1000	  (adrenaline	  1:1000	  =	  0.01mg	  per	  0.01mL).	  
Approximate	  age	  and	  weight	   	  Adrenaline	  dose	  
<1	  year	  (approx.	  5–10	  kg)	   	  	   0.05–0.1	  mL	  
1–2	  years	  (approx.	  10	  kg)	   	  	   0.1	  mL	  
2–3	  years	  (approx.	  15	  kg)	   	  	   0.15	  mL	  
4–6	  years	  (approx.	  20	  kg)	   	  	   0.2	  mL	  
7–10	  years	  (approx.	  30	  kg)	  	  	   0.3	  mL	  
10–12	  years	  (approx.	  40	  kg)	   	  0.4	  mL	  
>12	  years	  and	  adult	  (over	  50	  kg)	   	  0.5	  mL	  
	  
Route:	  deep	  IM.	  Where	  possible	  administer	  in	  a	  non-­‐injected	  limb,	  in	  either	  the	  deltoid	  or	  vastus	  lateralis.	  	  
You	  can	  expect	  to	  see	  some	  response	  to	  the	  adrenaline	  within	  1	  –	  2	  minutes.	  If	  necessary,	  adrenaline	  can	  be	  
repeated	  at	  5	  –	  15	  minute	  intervals,	  to	  a	  maximum	  of	  three	  doses,	  while	  waiting	  for	  assistance.	  Use	  alternate	  
sites/limbs	  for	  additional	  doses.	  	  
ADMINISTER	  OXYGEN	  (if	  available)	  at	  high	  flow	  rates	  where	  there	  is	  respiratory	  distress,	  stridor	  or	  wheeze.	  	  
IF	  HYPOTENSIVE,	  ELEVATE	  LEGS	  
IF	  STRIDOR	  IS	  PRESENT,	  ELEVATE	  HEAD	  AND	  CHEST	  
RECORD	  VITAL	  SIGNS	  even	  5	  –	  10	  minutes.	  All	  observations	  and	  interventions	  need	  to	  be	  clearly	  documented	  
in	  medical	  notes	  and	  should	  accompany	  the	  individual	  to	  hospital.	  	  
ADMIT	  TO	  HOSPITAL	  –	  all	  cases	  of	  anaphylaxis	  should	  be	  admitted	  to	  hospital	  for	  observation.	  Rebound	  
anaphylaxis	  can	  occur	  12	  –	  24	  hours	  after	  the	  initial	  episode.	  	  
Note:	  only	  medical	  practitioners	  should	  administer	  IV	  adrenaline,	  and	  then	  only	  1:10,000	  dilution	  at	  a	  dose	  of	  




Appendix	  3:	  Pharmacist	  Administered	  Vaccination	  Checklist	  
	  
Pharmacist	  Administered	  Vaccination	  Checklist 
Equipment	  
o Fridge	  
o Phone	  access	  
o Min.	  3x	  ANAPEN/EPIPEN	  or	  	  
o Adrenaline	  1:1000	  (three	  
ampoules)	  
o Adrenaline	  1:1000	  dose	  chart	  
o Syringes	  1.0ml	  Tuberculin,	  not	  
insulin	  syringes	  (insulin	  needles	  
are	  too	  short	  for	  an	  IM	  injection)	  
o Needles	  –	  range	  including	  23	  or	  
25	  G	  x	  25mm,	  22G	  x	  38mm	  
o Sharps	  container	  
o Alcohol	  swabs	  
o Cotton	  balls	  
o Gauze	  
o Thermometer	  (for	  taking	  patient	  
temperature)	  optional	  	  
o Blood	  pressure	  monitor	  optional	  
o Influenza	  vaccine	  
o Fridge	  temp:	  data	  monitor/Min-­‐max	  
thermometer	  
o Disposable	  gloves	  
o Hand	  sanitiser	  
o Timer	  (to	  monitor	  customer	  waiting	  times	  
once	  they	  have	  had	  the	  vaccination)	  
o Latest	  copy	  of	  Immunisation	  Handbook	  
o Hazardous	  waste	  bin	  and	  a	  replacement	  
o Esky,	  polystyrene	  foam,	  shredded	  paper	  
and	  ice	  blocks	  (if	  there	  is	  a	  power	  outage)	  	  
o Wash	  basin	  and	  soap	  




o Garbage	  bin	  
o Room	  with	  two	  chairs,	  desk	  and	  computer	  
with	  internet	  access	  if	  possible	  
o Waiting	  area	  




o Patient	  consent	  
o Fridge	  temperature	  document	  (QCPP	  -­‐T5C)	  
o Pre-­‐vaccination	  checklist	  
o How	  to	  recognise	  anaphylaxis	  Poster	  	  
o Emergency	  equipment	  checklist	  
o Posters	  
o Letter	  to	  doctors	  
o Letter	  to	  local	  business	  
o Booking	  Schedule	  
o Factsheet	  to	  give	  to	  customers	  	  
o Booking	  instructions	  
o Instructions	  for	  Use	  
o Current	  First	  Aid,	  completed	  QPIP	  training	  
course	  certificate,	  CPR	  certificate	  (or	  
documentation	  showing	  these	  courses	  
have	  been	  completed)	  




Appendix	  4:	  Patient	  Pre-­‐vaccination	  Checklist	  for	  Pharmacist	  –	  Influenza	  (Example)	  
Patient	  Pre-­‐vaccination	  Checklist	  for	  Pharmacist	  –	  Influenza	  
A	  trained	  pharmacist	  must	  conduct	  the	  pre-­‐vaccination	  consultation,	  consent	  process	  and	  vaccine	  administration.	  
Date:	  ___/______/_____Customer	  name:_________________________________________________________	  
	  Phone	  number:____________________________DOB:_______/_________/__________	  
Customer	  address:___________________________________________________________________________	  
GP	  name/address/phone	  number:	  ______________________________________________________________	  
__________________________________________________________________________________________	  
CONSULTATION	  QUESTIONS	   RECORD	  
YES/NO	  
WHEN	  TO	  REFER	  
Is	  the	  customer	  younger	  than	  18?	   	   If	  yes,	  refer	  to	  GP	  
Is	  the	  customer	  older	  than	  59	  years?	  	   	   If	  yes:	  intramuscular	  injection	  route	  is	  required.	  If	  
older	  than	  65	  years,	  the	  patient	  is	  eligible	  for	  a	  
funded	  vaccination.	  	  	  
Is	  the	  customer	  younger	  than	  65	  years	  and	  have	  a	  
chronic	  illness	  or	  are	  pregnant?	  	  
	   If	  yes	  to	  age	  criteria	  and	  health	  condition,	  refer	  to	  
GP	  for	  funded	  vaccine.	  
Is	  the	  customer	  allergic	  to	  eggs,	  egg	  products	  or	  
chicken	  proteins?	  
	   If	  yes,	  refer	  to	  GP	  
Is	  the	  customer	  allergic	  to	  neomycin	  or	  other	  vaccine	  
components?	  
	   If	  yes,	  refer	  to	  GP	  
Is	  the	  customer	  unwell	  today?	  (NB:	  okay	  to	  vaccinate	  if	  
they	  are	  mildly	  unwell	  but	  afebrile,	  i.e.	  temperature	  
less	  than	  38	  degrees	  C).	  	  
	   If	  yes,	  refer	  to	  GP	  
Has	  the	  customer	  ever	  had	  a	  severe	  reaction	  to	  any	  
vaccine?	  
	   If	  yes,	  refer	  to	  GP	  
Is	  the	  customer	  taking	  immunosuppressant	  medicines?	   	   If	  yes,	  refer	  to	  GP	  
Has	  the	  customer	  had	  a	  severe	  allergic	  reaction	  from	  
any	  cause?	  (Excluding	  insect	  bites	  and	  bee	  strings.)	  
	   If	  yes,	  refer	  to	  GP	  
Does	  the	  customer	  have	  any	  neurological	  conditions?	  
(Potential	  risk	  of	  recurrence	  of	  Guillain-­‐Barre	  
syndrome,	  neuritis,	  encephalomyelitis	  and	  other)	  





















































Appendix	  12:	  Adult	  Vaccines	  available	  for	  administration	  by	  route	  (refer	  to	  CMI)	  
Vaccines for intramuscular administration 
• Agrippal – Novartis Vaccines and Diagnostics Pty Ltd (inactivated influenza virus). Each 0.5 
mL pre-filled syringe contains 15 µg haemagglutinin of each of the three recommended strains. 
May contain traces of kanamycin, neomycin, formaldehyde, barium sulphate, cetrimonium 
bromide (CTAB), polysorbate 80 and egg protein. 
• Fluarix – GlaxoSmithKline (inactivated influenza virus). Each 0.5 mL pre-filled syringe contains 
15 µg haemagglutinin of each of the three recommended strains. May contain traces of 
formaldehyde, gentamicin, polysorbate 80, octoxinol 10 and egg protein. 
• Inf luvac – Abbott Products Pty Ltd (inactivated influenza virus). Each 0.5 mL pre-filled syringe 
contains 15 µg haemagglutinin of each of the three recommended strains. May contain traces of 
formaldehyde, CTAB, polysorbate 80, gentamicin and egg protein. 
• Vaxigrip – Sanofi Pasteur Pty Ltd (inactivated influenza virus). Each 0.5 mL pre-filled syringe 
contains 15 µg haemagglutinin of each of the three recommended strains. May contain traces of 
formaldehyde, octoxinol 9, neomycin and egg protein. 
• Fluvax – CSL Limited (inactivated influenza virus). Each 0.5 mL pre-filled syringe contains 15 
µg haemagglutinin of each of the three recommended strains. May contain traces of neomycin, 
polymyxin B, β-propiolactone, sodium taurodeoxycholate and egg protein. 
 
Adults aged ≥65 years 
• Fluad – Novartis Vaccines and Diagnostics Pty Ltd (inactivated influenza virus). Each 0.5 mL 
pre-filled syringe contains 15 µg haemagglutinin of each of the three recommended strains, 
adjuvanted with MF59C.1 (which contains squalene and polysorbate 80). May contain traces of 
kanamycin, neomycin, formaldehyde, barium sulphate, CTAB and egg protein. 
 
Vaccines for intradermal administration 
Adults aged 18–59 years 
• Intanza 9 μg – Sanofi Pasteur Pty Ltd (inactivated influenza virus). Each 0.1 mL pre-filled 
purpose-designed Micro-Injection System contains 9 µg haemagglutinin of each of the three 






























































Appendix	  21:	  QPIP1	  Approved	  Site	  List	  	  
































Mt	  Gravatt	  Plaza	  
Mt	  Ommaney	  (Shop	  1)	  






















North	  Queensland	  arm:-­‐	  
Alive	  Discount	  Pharmacy	  -­‐	  Abbott	  Street	  
Kuranda	  Pharmacy	  
V	  Pharmacy	  -­‐	  Smithfield	  
Yungaburra	  Pharmacy	  
Calanna	  Pharmacy	  Woree	  
Calanna	  Pharmacy	  Edmonton	  
Marlin	  Coast	  Amcal	  	  
Discount	  Drug	  Stores	  Pease	  Street	  
Annandale	  Pharmacist	  Advice	  Pharmacy	  
Amcal	  Pharmacy	  Cannonvale	  
Amcal	  Robert	  Poole's	  Pharmacy	  
Bluewater	  Pharmacy	  
Calanna	  Pharmacy	  Kirwan	  
Calanna	  Pharmacy	  Aitkenvale	  
Alive	  Pharmacy	  JCU	  
Livelife	  Pharmacy	  Airlie	  Beach	  
AFS	  Friendly	  Care	  Pharmacy	  
Dupuy's	  Pharmacy	  
Healthpoint	  Northside	  Mater	  Pharmacy	  
Healthpoint	  Northern	  Beaches	  Mackay	  
Healthpoint	  Day	  and	  Night	  Mackay	  
Bowen	  Plaza	  Pharmacy	  
Bowen	  Healthcare	  Pharmacy	  
Emerald	  Pharmacy	  First	  	  
Amcal	  Max	  Yeppoon	  Central	  Pharmacy	  
LiveLife	  Pharmacy	  Keppel	  Plaza	  
LiveLife	  Pharmacy	  Gracemere	  
Gracemere	  Amcal	  Pharmacy	  




Appendix	  22:	  Approved	  Pilot	  Site	  Certificate	  (Example)	  	  
 
